News

Dragon Pharmaceuticals Inc. is pleased to announce that it has appointed Ms. Rita Jervis as VP Corporate Development. Ms. Jervis will be responsible for leading the company’s strategic planning, business development, and investor relations initiatives. Ms. Jervis brings to her position 14 years of planning and operations experience in the biotechnology sector. In her position […]

Dragon Pharmaceuticals is pleased to announce a number of significant developments in its international marketing of Erythropoietin (“EPO”) since its last international marketing update on October 6, 2000. Itaca Laboratories, Ltd., of Brazil, a licensee and distributor of the Company’s EPO has filed all requisite documents with Brazilian health authorities for the registration of EPO. […]

Dragon Pharmaceuticals Inc. (“Dragon”) is pleased to announce the completion of its recent private placement of 3,500,000 units (the “Units”) at a price of US$2.00 per unit. Each Unit consists of one common share and one non-transferable share purchase warrant (the “Warrant”). Each Warrant entitles the holder to purchase one half common share at a […]

Dragon Pharmaceuticals Inc. is pleased to announce that the Board of Directors has approved the extension of the Company’s outstanding common share purchase warrants for a period of 2 months. The exercise price remains at $2.50 and the warrants may be exercised until March 1st, 2001. Dragon Pharmaceuticals is an international biopharmaceutical corporation engaged in […]

Dragon Pharmaceuticals Inc. (OTCBB – DRUG.OB) is pleased to announce that the Drug Controller General of India has issued regulatory clearance for the import and sale of Dragon’s recombinant Erythropoietin (EPO) to India. Dragon has previously also received regulatory approval for sale of its EPO in China, Egypt, and Peru for use in anemia associated […]

Dragon Pharmaceuticals Inc. has recently signed licensing agreements with three overseas pharmaceutical companies, gaining the Company a foothold in both Latin America and Southeast Asia. In August the company signed a license and distribution agreement with Duopharma (M) SDN BHD, of Malaysia, granting Duopharma rights to market the Company¡¦s flagship recombinant Erythropoietin for injection (epoetin-alfa) […]

The Company is pleased to announce that The State Drug Administration (SDA) of China (China¡¦s equivalent to the FDA in the United States) has recently granted a certificate of Good Manufacturing Practices (GMP) to Dragon¡¦s subsidiary Huaxin Pharmaceutical and Bioengineering Co. Ltd., following an inspection of Huaxin¡¦s plant in July of this year. The GMP […]

The Company is pleased to announce revenues of US$817,500 from the sale of Erythropoietin in China for the first quarter of 2000. During the first quarter the Company recorded sales of 58,870 units, representing an increase of 60% over sales and revenues in the last quarter of 1999. Dragon is currently in the late stages […]

Dragon Pharmaceuticals Inc. is pleased to announce that Nanjing Huaxin Biotech Co., Ltd. has acquired co-development rights to a Pichia yeast culture system for the production of TPO from Kelong Industrial Co., Ltd, a Chinese company. Dragon holds a 75% equity interest in Nanjing Huaxin. TPO is a blood growth factor that stimulates the production […]

Dragon Pharmaceuticals Inc. is very pleased to announce the appointment of international financier Robert Friedland to the Board of Directors, effective immediately. Friedland is chairman and president of Ivanhoe Capital Corporation, a Singapore-based venture capital company with worldwide interests in resource and high-tech companies. Companies developed or financed by Friedland and Ivanhoe Capital include Ivanhoe […]